Clarification on reported halt at Assam eye-care plant

Plant shut by a regulatorCapex & Operations View source PDF Explain this filing

SUNPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.1%Reaction day

₹1776.40

prior close

₹1785.30

announcement price

In-mkt

timing

Nifty 100market+0.8%-0.8% vs market

Pharmaceuticals peers, median of 173sector+0.8%-0.7% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty 100 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.4

10m

+0.4

15m

+0.3

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.1+0.8-0.8+0.8-0.7

Next day

+3.4pendingpending+1.6+1.8

+4.7pendingpending+1.5+3.3

—————

15d

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sun Pharma said the report about an India-ordered halt to eye-care drug production at its Assam facility related to developments in August 2026, not a new event on 30 October. It said the share-price movement after its September-quarter and half-year results could not be attributed to the report or any other known factor.

Likely market impact

The clarification may ease uncertainty, but the reported production halt remains a regulatory risk. No restart date or financial impact was provided.